Search

Your search keyword '"Beesley, A."' showing total 36 results
Start Over Author "Beesley, A." Journal lung cancer
36 results on '"Beesley, A."'

1. 139 A retrospective review of lung cancer patients receiving whole brain radiotherapy treated at the Kent Oncology Centre (KOC) in 2014, audited against the QUARTZ trial

Author

C. Mikropoulos, G. Hegarty, H. Taylor, R. Burcombe, J.Y. Turner, J. Hall, M. Cominos, Riyaz Shah, T. Sevitt, S. Beesley, and M. Hadaki

Subjects
Pulmonary and Respiratory Medicine, Cancer Research, Retrospective review, medicine.medical_specialty, Oncology, business.industry, General surgery, Whole brain radiotherapy, medicine, business, Lung cancer, medicine.disease, Intensive care medicine
Published
2016
Full Text
View/download PDF

8. 66: Adjuvant chemotherapy dose delivery for completely resected NSCLC in a regional cancer centre: analysis of outcomes by age and comorbidity

Author

Rushabh Shah, S. Wood, J. Hall, H. Taylor, T. Sevitt, R. Li, R. Burcombe, S. Beesley, M. Cominos, and J. Brown

Subjects
Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Dose delivery, Adjuvant chemotherapy, business.industry, medicine.disease, Comorbidity, Regional cancer, Internal medicine, medicine, business
Published
2015
Full Text
View/download PDF

9. 17: Surgery for lung cancer in nonagenarians: a new dawn approaches

Author

Tom Routledge, M. Ghosh-Dastidar, Karen Harrison-Phipps, John Pilling, S. Wakelin, Henrietta Wilson, and S. Beesley

Subjects
Pulmonary and Respiratory Medicine, Thorax, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, medicine.disease, Right pulmonary artery, Surgery, Lesion, Pneumonectomy, Oncology, medicine.artery, Radiological weapon, Pulmonary artery, medicine, Sarcoma, medicine.symptom, Lung cancer, business
Abstract

A computed tomography (CT) thorax demonstrated abnormal opacification within the right pulmonary artery (RPA). The patient was initially diagnosed with PE and anticoagulation treatment commenced. Despite anticoagulation both the symptoms and radiological abnormalities were unchanged 1 month later and she was referred to a tertiary centre for evaluation. Positron emission tomography computed tomography (PET-CT) revealed abnormal uptake within the RPA. Pulmonary angiogram confirmed an obstructing lesion, from which aspiration tissue sampling confirmed a high-grade pleomorphic sarcoma of the pulmonary artery. The patient underwent a right pneumonectomy followed by adjuvant chemotherapy. Conclusion: Pulmonary artery sarcomas are rare tumours with only a few hundred reported cases. Delay in diagnosis is frequent with PE the most common misdiagnosis. Clinical features that may raise suspicions of pulmonary artery sarcoma in patients with suspected PE include fever, weight loss, clubbing and elevated inflammatory markers such as CRP. Surgical resection as part of multi-modality therapy has improved survival for patients from an average of 1.5 months without treatment to approximately 3 years in the largest analysis of outcomes of this rare tumour. Disclosure: All authors have declared no conflicts of interest.

Published
2015
Full Text
View/download PDF

10. A Kent and Medway Cancer Network (KMCN) audit of second-line treatment for non-small cell lung cancer

Author

S. Beesley, M. Cominos, M. Jamal-Hanjani, R. Burcombe, T. Sevitt, R. Shah, H. Taylor, and C. Cafferkey

Subjects
Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Second line treatment, business.industry, Cancer, Audit, medicine.disease, Internal medicine, medicine, Non small cell, Lung cancer, business
Published
2010
Full Text
View/download PDF

11. 15 Oral vinorelbine in combination with carboplatin for the treatment of inoperable non-small cell lung cancer (NSCLC) —the Kent Experience

Author

R. Raman, R. Shah, R. Burcombe, S. Beesley, and H. Taylor

Subjects
Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, non-small cell lung cancer (NSCLC), medicine.disease, Vinorelbine, Carboplatin, chemistry.chemical_compound, chemistry, Internal medicine, medicine, business, medicine.drug
Published
2007
Full Text
View/download PDF

16. 83 Lung cancer diagnosis and management in patients over 80 years – An audit of practice in Kent for 2011/2012

Author

M. Cominos, R. Burcombe, Rushabh Shah, S. Beesley, A. Visioli, T. Sevitt, H. Taylor, C. O'Hanlon Brown, and Stuart Young

Subjects
Pulmonary and Respiratory Medicine, Cancer Research, Pediatrics, medicine.medical_specialty, Oncology, business.industry, General surgery, medicine, In patient, Audit, business, Lung cancer, medicine.disease
Published
2014
Full Text
View/download PDF

17. 145 Radical chemoradiation in non-small cell lung cancer – does the number of chemotherapy cycles matter?

Author

H. Taylor, R. Burcombe, S. Beesley, C. Baldry, A. Visioli, R. Shah, M. Cominos, T. Sevitt, and K. Sambasivan

Subjects
Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, medicine.disease, Internal medicine, medicine, Non small cell, business, Lung cancer
Published
2014
Full Text
View/download PDF

18. 183 Treating extensive stage small cell lung carcinoma in poor performance status patients – is a high 30 day mortality rate justifiable?

Author

R. Burcombe, A. Visioli, T. Bird, M. Cominos, A. Shiarli, R. Shah, S. Beesley, H. Taylor, and T. Sevitt

Subjects
Pulmonary and Respiratory Medicine, Cancer Research, medicine.medical_specialty, Oncology, 30 day mortality, business.industry, Extensive Stage Small Cell Lung Carcinoma, medicine, Poor performance status, Intensive care medicine, business
Published
2014
Full Text
View/download PDF

20. 94 A review of the management of mesothelioma patients who received second line chemotherapy within the Kent Oncology Centre Network

Author

A. Visioli, R. Burcombe, T. Sevitt, M. Cominos, H. Taylor, A. Shiarli, S. Beesley, and A. Georgiou

Subjects
Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Internal medicine, medicine, Mesothelioma, medicine.disease, business, Second line chemotherapy
Published
2013
Full Text
View/download PDF

24. 153 A review of concurrent chemoradiotherapy using cisplatin and oral vinorelbine in patients with non-small cell lung cancer (NCSLC) at the Kent Oncology Centre

Author

C. Baldry, H. Taylor, A. Visioli, T. Sevitt, M. Cominos, R. Shah, R. Burcombe, and S. Beesley

Subjects
Pulmonary and Respiratory Medicine, Cisplatin, Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.disease, Vinorelbine, Concurrent chemoradiotherapy, Internal medicine, medicine, In patient, Non small cell, Lung cancer, business, medicine.drug
Published
2012
Full Text
View/download PDF

25. 14 Audit of the management of epithelial growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients within the Kent Oncology Centre and its associated units

Author

R. Shah, S. Beesley, A. Biondo, H. Taylor, T. Sevitt, R. Burcombe, and M. Cominos

Subjects
Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Mutant, non-small cell lung cancer (NSCLC), Audit, medicine.disease, Growth factor receptor, Internal medicine, medicine, business
Published
2012
Full Text
View/download PDF

29. 19 A Kent and Medway Cancer Network (KMCN) audit of first-line treatment with cisplatin/pemetrexed (CisPem) in non squamous non-small cell lung cancer (NSCLC)

Author

R. Burcombe, I. Letsa, M. Cominos, T. Sevitt, S. Beesley, C. Mikropoulos, and A. Visioli

Subjects
Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, education.field_of_study, Performance status, business.industry, medicine.medical_treatment, Population, non-small cell lung cancer (NSCLC), Cancer, medicine.disease, Regimen, Pemetrexed, Internal medicine, medicine, education, business, Progressive disease, medicine.drug
Abstract

Introduction: NICE approved CisPem for first-line treatment of advanced large cell or adenocarcinoma NSCLC patients in September 2009. We reviewed outcomes for this regimen within KMCN, a large cancer network of 1.8 million population. Therapy was given at 7 sites within a nurse led model incorporating close clinical oversight. Methods: A retrospective analysis of patients receiving CisPem as first-line treatment for NSCLC (September 2009 August 2010) was undertaken. Results: 39 chemotherapy-naive patients with locally advanced or metastatic non-squamous NSCLC were identified; 37 were treated with CisPem. Baseline demographics are shown below: 59% male; median age 63 years; smoking status 27% current, 32% previous, 38% unknown, 2.7% never-smokers; stage at presentation III = 22%, IV = 70%; performance status PS = 0 8%, PS = 1 84%, PS = 2 5%. Five patients did not receive treatment due to rapid progression. A median of 4 cycles of chemotherapy was delivered: 67% completed 4 cycles, 5.4% received 6 cycles, 13% only completed 1 2 cycles. Of 109 cycles of chemotherapy, just 0.9% of cycles were delayed. Cisplatin dose was reduced or omitted in 7% and 5% of cycles respectively. Pemetrexed doses were reduced or omitted in 4% and 5% of cycles respectively. 25% of patients were admitted at some point during their chemotherapy. The reasons for admission were non-neutropenic sepsis (12%), thromboembolic phenomena (24%) and progressive disease (64%). There were no deaths within 30 days of CisPem administration. Partial responses were documented in 62.5% of cases. Stable disease was seen in 12.5% and progressive disease in 25%. As of August 2010, 12 patients had died (median overall survival of 6.5 months and median progression-free survival 6.0 months). Conclusions: First line CisPem delivered within a community/nurseled setting provides similar efficacy outcomes to published trial data. The high rate of hospital admission and thromboembolic complications warrants further investigation.

Published
2011
Full Text
View/download PDF

31. Mesothelioma in the Kent and Medway Cancer Network: A comprehensive review of 2 years of pemetrexed-based chemotherapy

Author

H. Taylor, M. Nawrocka, T. Sevitt, M. Cominos, R. Shah, C. Mikropoulos, S. Beesley, and R. Burcombe

Subjects
Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Cancer, medicine.disease, Pemetrexed, Internal medicine, medicine, Mesothelioma, business, medicine.drug
Published
2010
Full Text
View/download PDF

32. Radial radiotherapy versus high dose palliative radiotherapy with or without chemotherapy in non small cell lung carcinoma (NSCLC): Retrospective analysis of overall survival

Author

R. Burcombe, R. Shah, M. Cominos, H. Taylor, A. Lo, T. Sevitt, S. Beesley, and P. Brulinski

Subjects
Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Chemotherapy, medicine.medical_specialty, Lung, business.industry, medicine.medical_treatment, medicine.disease, Radiation therapy, medicine.anatomical_structure, Palliative radiotherapy, Internal medicine, Carcinoma, medicine, Overall survival, Retrospective analysis, Non small cell, business
Published
2010
Full Text
View/download PDF

34. An analysis of rate of admissions to an inpatient facility across 3 trusts in relation to the delivery of docetaxel chemotherapy in non small cell lung cancer (NSCLC)

Author

R. Shah, S. Beesley, R. Burcombe, A. Lo, T. Sevitt, A. Sharma, B. Patrick, D. Mukherji, and H. Taylor

Subjects
Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Inpatient facility, non-small cell lung cancer (NSCLC), medicine.disease, Docetaxel, Internal medicine, medicine, business, medicine.drug
Published
2009
Full Text
View/download PDF

36. Routine day 8 blood tests are not necessary for patients with non-small cell lung cancer treated with oral vinorelbine-carboplatin chemotherapy

Author

H. Taylor, R. Shah, H.C. Swannie, S. Lowe, and S. Beesley

Subjects
Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Chemotherapy, medicine.medical_specialty, business.industry, medicine.medical_treatment, Vinorelbine, medicine.disease, Carboplatin, chemistry.chemical_compound, chemistry, Internal medicine, medicine, Non small cell, business, Lung cancer, medicine.drug
Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results